Peter Bühlmann is a Professor at ETH Zürich within the Seminar für Statistik , focusing on high-dimensional statistics, causal inference, and machine learning. His work bridges theoretical advancements with practical software implementations in R packages like pcalg , mboost , and glmmlasso , impacting fields such as genomics, proteomics, and intensive care analytics. Key Contributions : Causal structure learning, stability selection, anchor regression, and deconfounding. Software : Developed widely used R packages for statistical modeling and causal inference. Teaching : Courses on high-dimensional statistics at ETH Zürich and international institutions. Research Trends : Recent articles emphasize causal robustness, domain adaptation, and applications in medicine. His work addresses challenges in heterogeneous data, missing values, and covariate shifts using methods like spectral deconfounding and residual prediction tests. Scientific Recognition : Co-author of a paper designated as a New Hot Paper (Meinshausen and Bühlmann, 2006) by Essential Science Indicators, indicating significant impact in high-dimensional multiple testing.
Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .
Associate Professor Adam Irwin is an NHMRC Emerging Leadership Fellow and Associate Professor in Infectious Diseases at the University of Queensland (UQ) and Queensland Children’s Hospital. He holds positions within the UQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences. His work focuses on early sepsis recognition, antimicrobial stewardship, and pediatric infectious diseases. Dr. Irwin completed his medical degree at the University of Birmingham and his PhD in 2016 from the University of Liverpool’s Institute of Infection and Global Health. He has led initiatives like the Queensland Paediatric Sepsis Program, recognized with a Global Sepsis Alliance Award and Queensland Health Excellence Awards. His research spans sepsis pathway implementation, antimicrobial resistance trends, and rapid diagnostic tools. Notable grants include NHMRC funding for studies on multi-drug resistant infections and Children’s Hospital Foundation support for genomics and antimicrobial stewardship projects. He supervises PhD candidates in areas like bloodstream infections and molecular diagnostics. Dr. Irwin collaborates across institutions, contributing to projects such as the RAPIDS Study Group and the PAEDS surveillance network. Awards include the NHMRC Emerging Leadership Fellowship and recognition for sepsis program excellence. His work emphasizes translating research into clinical practice, improving outcomes for critically ill children through evidence-based protocols and innovative diagnostics.
Itsik Pe'er is a Full Professor and Vice-Chair in the Department of Computer Science at Columbia University's Fu Foundation School of Engineering & Applied Science, and holds a joint appointment as Professor of Systems Biology at the Vagelos College of Physicians and Surgeons. His research focuses on computational methods in human genetics, including genetic variation analysis, disease association studies, and algorithm development for genomic data. He leads the Itsik Pe'er Lab of Computational Genomics, which develops tools like Xplorigin, Germline, and SEACells to address challenges in genomics and medical research. His work spans machine learning applications in healthcare, microbiome analysis, and cancer genomics. Notable contributions include studies on hypertensive disorders in pregnancy, bias correction in predictive models, and the development of non-Euclidean learning libraries like Manify. Pe'er has advised students including Vladimir Vacic, Anat Kreimer, and Arthi Ramachandran, and collaborates on grants addressing genetic epidemiology and computational biology. His lab's location is in the Computer Science Building at Columbia's Morningside Campus.
Antti Honkela is a Professor of Data Science at the University of Helsinki's Department of Computer Science, within the Faculty of Science. He also serves as the Coordinating Professor for the Privacy-preserving and Secure AI Research Programme at the Finnish Center for Artificial Intelligence (FCAI), and as Deputy Director of the Master's Programme in Data Science. His roles include membership in the Health and Social Data Permit Authority (Findata) and as an Action Editor for Transactions on Machine Learning Research. Honkela's research focuses on privacy-preserving machine learning, differential privacy, Bayesian methods, and their applications in computational biology and healthcare. He leads projects such as the European Lighthouse in Secure and Safe AI (ELSA) and the Data Literacy for Responsible Decision-making initiative. His work emphasizes developing robust frameworks for privacy-aware AI, including differentially private synthetic data and federated learning. Honkela has advised numerous PhD and Master's students, and his contributions span theoretical advancements and practical implementations, such as the D3p Python package for differentially private probabilistic programming. Key contributions include advancements in Bayesian inference from synthetic data, privacy accounting mechanisms, and computational methods for genomic epidemiology. His interdisciplinary approach bridges machine learning, statistics, and healthcare, addressing challenges in data privacy and secure AI deployment.
Professor Guy Williams is a leading academic at the University of Cambridge with a focus on imaging science and clinical neurosciences, affiliated with Downing College and the Wolfson Brain Imaging Centre . Holding a PhD in Physics from his initial Natural Sciences degree, he specializes in nuclear magnetic resonance (NMR) and MRI techniques for brain imaging. Education: BA, PhD in Physics His research centers on non-invasive imaging of brain structure and function, particularly in traumatic brain injury (TBI) and dementia. His work involves developing novel MRI pulse sequences and advanced data analysis algorithms, including AI-based diagnostic tools. He leads studies on white matter integrity post-trauma, longitudinal dementia assessment, and applications of MRI in disorders of consciousness and addiction. Recent publications highlight collaborations in traumatic brain injury outcomes, AI-guided dementia prediction, and neuroimaging of post-COVID cognitive deficits. His team's work on ultra-high field laminar fMRI and distortion correction methods has advanced clinical neuroscience applications. Key techniques include diffusion tensor imaging (DTI), 7 Tesla MRI, and positron emission tomography (PET/MR). His research spans from basic NMR physics to clinical translation, with a strong emphasis on multi-site studies and real-world diagnostic implementation.
Yasushi Sakurai is a Professor in the Department of Translational Datability at Osaka University's Institute of Scientific and Industrial Research, co-leading the Sakurai and Matsubara Laboratory within the Center for Industrial Science and AI. His research mission focuses on transforming society through real-time prediction of natural and social phenomena using large-scale data analytics, with emphasis on practical technological implementation. His research spans time-series big data analysis, dynamic learning systems, and real-time information provision. Key areas include tensor stream mining, EEG-based healthcare applications, cybersecurity anomaly detection, and multi-omics cancer subtyping. The lab specializes in developing deployable technologies that optimize social activities through predictive modeling of evolving data streams. Recent publications (2023-2025) reveal concentrated innovation in time-series data stream processing, with dominant themes in tensor analytics, frequency-domain forecasting, and causal modeling. His team produces high-impact work accepted at premier AI venues (ICLR, AAAI, KDD, WWW), consistently featuring oral presentations that highlight technical novelty and societal relevance. Scientific Awards: FY2024 Minister of Education, Culture, Sports, Science and Technology Award for Science and Technology (Research Category) for dynamic learning and real-time data stream analysis Professor Sakurai mentors graduate students including Naoki Chihara (DEIM2024 Outstanding Paper Award winner), Yuka Tamura (DEIM2024 Student Presentation Award winner), and Ren Fujiwara. His lab maintains active industry-academia partnerships focused on practical technology deployment, with research directly addressing real-world challenges in healthcare monitoring and cybersecurity. The Sakurai and Matsubara Laboratory operates as a dynamic research unit within Osaka University's Center for Industrial Science and AI, structured around specialized teams for tensor stream analysis, medical data mining, and network dynamics. Current projects emphasize real-time prediction systems with immediate societal applications, supported by strong industry collaboration frameworks.
Dr. Michael Baym is an Associate Professor of Biomedical Informatics at Harvard Medical School with affiliate appointments in Microbiology and the Laboratory of Systems Pharmacology, and as an Associate Member of the Broad Institute. He leads the Baym Lab, which studies microbial evolutionary genomics and antibiotic resistance through a hybrid of experimental, computational, and theoretical approaches. His research focuses on: Antibiotic Resistance Evolution and practical interventions Mobile Genetic Elements (plasmids, phages, transposons) Computational Genomic Algorithms for big data analysis Synthetic Biology tools and technologies Key recent publications explore phage discovery systems , phylogenetic compression of microbial genomes, and RNA-guided gene drives in plasmids. His work is supported by multiple NIH/NIGMS and NSF grants including a MIRA award. Scientific honors include: Packard Fellowship (2018) Pew Biomedical Scholarship (2020) Sloan Research Fellowship (2020) A. Clifford Barger Excellence in Mentoring Award (2021) SSQBio Mentorship Award (2022) The lab actively trains PhD students and postdoctoral fellows with alumni occupying academic and industry positions globally. Current team members include researchers from interdisciplinary backgrounds working at the intersection of experiment, computation, and theory .
Todd A. Alonzo is a Professor of Research in the Department of Preventive Medicine at the University of Southern California . As Group Statistician for the Children's Oncology Group , he focuses on statistical methods for biomarker analysis, medical diagnostic testing, and clinical trial design in pediatric acute myeloid leukemia (AML). Education: B.S. in Statistics, California State Polytechnic University (1994) MS and PhD in Biostatistics, University of Washington (1997, 2000) Research Interests include: Development of statistical frameworks for diagnostic accuracy Genomic and proteomic profiling in AML Pharmacogenomic score systems for chemotherapy response Non-inferiority trial design in low-event-rate settings Health disparities in pediatric oncology Scientific Awards : Fellow, American Statistical Association (2018) Outstanding Teacher Award, International Society for Magnetic Resonance in Medicine (2017) NIH Predoctoral Cardiovascular Biostatistics Training Grant (1995) ENAR Biometrics Society Distinguished Student Paper Award (1999) WNAR Biometrics Society Best Student Oral Presentation (1999) Leadership & Service includes editorial board memberships (Biometrics, Pediatric Blood & Cancer, Biometrical Journal), reviewer for 30+ scientific journals, and roles on multiple Data Safety and Monitoring Boards. He served as President of the International Biometric Society Western Northern America Region (WNAR) in 2009.
Timo Minssen is Professor of Law at the University of Copenhagen (UCPH) and the Founding Director of UCPH's Center for Advanced Studies in Bioscience Innovation Law (CeBIL). He also holds affiliations as an LML Research Affiliate at the University of Cambridge and an Inter-CeBIL Research Affiliate at Harvard Law School's Petrie-Flom Centre. With extensive expertise in Intellectual Property, Competition, and Regulatory Law, Minssen focuses on the legal aspects of emerging health and life science technologies, including genome editing, big data, artificial intelligence, and quantum technology. His educational background includes a German law degree (Staatsexamen) from Georg-August-University in Göttingen, and Swedish biotech & IPR related LL.M., LL.Lic., and LL.D. degrees from Lund University and Uppsala University. His PhD thesis on the patentability of biopharmaceutical technology in the US & Europe received the prestigious Swedish King Oscar award. 2024: TUM Global Visiting Professor, Technical University of Munich (Germany) 2016: Visiting Research Fellow, University of Cambridge (UK) 2014: Visiting Research Fellow, University of Oxford (UK) 2013-14: Visiting Scholar, Harvard Law School (US) 2012: LL.D. - Doctor of Laws (Swedish "juris doktor"), EU/US patent law, Lund University, Sweden Minssen's research spans AI & Big Data in Health & Life Sciences, Sustainable and responsible innovation & tech transfer, Pharmaceutical-, Life Science- & Biotech Law, Comparative European & US Patent Law, Intellectual Property Law & Open Innovation, and EU Competition- & US Antitrust Law. His work addresses legal issues throughout the lifecycle of health and life science products and processes, from R&D regulation to technology transfer and commercialization. His extensive publication record includes 7 books and over 200 articles and book chapters published in leading journals such as Science, Nature Biotechnology, JAMA, and Harvard Business Review. His research has been featured in The Economist, Financial Times, and other major media outlets. Minssen's recent work shows a strong focus on AI regulation, quantum technology law, and data governance in health contexts, reflecting the evolving landscape of technology and law. Scientific Awards and Recognition King Oscar award for best Jur. Dr. thesis (2014) Jorcks Fonds Forsknings Pris (Jorck's Foundation Research Prize) (2017) Awapatent Research Prize (2009) Max Planck Research Scholarship (2005) Visiting Scholar appointments at Harvard Law School, University of Oxford, and University of Cambridge Recipient of a Novo Nordisk Foundation Grant for a "Collaborative Research Program in Biomedical Innovation Law" (2018) As an advisor, Minssen serves international organizations including the WHO, WIPO, and EU Commission. He has supervised numerous PhD students in areas including pharmaceutical law, biotechnology patents, and antimicrobial resistance. His current research projects include the Novo Nordisk Foundation's International Collaborative Bioscience Innovation & Law (Inter-CeBIL) Programme (50 million DKK), CLASSICA: EU Horizon Project on AI-assisted surgery, and AI@Care: Law and Ethics and Algorithmic Bias in Healthcare. Minssen leads the Center for Advanced Studies in Bioscience Innovation Law (CeBIL), which serves as a hub for interdisciplinary research on the intersection of law, technology, and innovation in the health and life sciences. The center collaborates with institutions worldwide to address pressing legal challenges in emerging technologies.
Dr. Thomas Chen is an Assistant Professor in the Department of Medicine-Hospital Medicine at the University of Chicago. He serves as Co-Director of the Personalized Therapeutics Clinic, focusing on integrating pharmacogenomics into clinical practice. Dr. Chen's primary research interests include pharmacogenomics, medical education, and hospital medicine. He has particular expertise in the medication reconciliation process, prescribing practices, and quality improvements that decrease healthcare costs while improving patient outcomes. His work bridges the gap between genomic medicine and practical clinical applications in hospital settings. Dr. Chen has made significant contributions to the implementation of pharmacogenomics in inpatient care. His research demonstrates how pharmacogenomic information can be effectively integrated into routine hospital practice to improve patient care, with a focus on care team dynamics, applicability for minority populations, and outcomes of various medication regimens in hospitalized patients. His work shows a clear trend toward practical implementation of pharmacogenomics in real-world clinical settings, with publications spanning from diagnostic methods (2012) to current cutting-edge research on care team attributes predicting successful pharmacogenomic implementation (2025). Dr. Chen holds dual training in pharmacy and medicine, providing him with a unique perspective on medication management and pharmacogenomics. His research has been published in high-impact journals including Clinical and Translational Science, Pharmacogenetics and Genomics, and Journal of Personalized Medicine.
Max Lau is an Assistant Professor in the Department of Biostatistics and Bioinformatics and the Department of Epidemiology at Emory University. His research focuses on integrating machine learning and computational methods with epidemiological and genomic data to study infectious disease dynamics. He teaches courses such as BIOS 790R (Advanced Seminar in Biostatistics) and DATA 534 (Applied Machine Learning). Dr. Lau's work emphasizes scalable Bayesian inference, graph neural networks, and stochastic modeling to address challenges in disease transmission, outbreak control, and pathogen evolution. His recent research includes developing tools like ScITree and Epilearn, and he has contributed to understanding measles dynamics, tuberculosis treatment, and livestock disease management. His academic contributions span over 30 publications since 2010, with a particular focus on phylodynamics, epidemic modeling, and vaccine strategy evaluation. His interdisciplinary approach bridges computational methods with public health applications, aiming to enhance disease prediction and intervention efficacy.
Dr. Ian Wilson is a researcher at Newcastle University with a focus on medical genetics, nephrology, and genomic analysis. His work spans genetic determinants of kidney diseases, mitochondrial disorders, and biomarker development. Notable contributions include studies on uromodulin genetics in African populations, copy-number variations in rare diseases, and kidney ciliopathies. He has collaborated extensively on projects involving genome sequencing, mitochondrial replacement therapy, and muscular dystrophy biomarkers. Wilson's research integrates computational tools like machine learning for predictive modeling in urolithiasis and employs advanced imaging techniques for disease progression monitoring. Key areas: Genetic epidemiology, renal genomics, mitochondrial DNA analysis Focus on translational applications: Biomarker development for kidney stones and muscular dystrophies Interdisciplinary collaborations in ophthalmology and orthopedics His publications reflect a commitment to advancing diagnostic accuracy and understanding complex genetic disorders through multi-omics approaches.
Lucas Janson is an Associate Professor of Statistics and Affiliate in Computer Science at Harvard University. He leads the Harvard Statistical Consulting Service, supervising PhD students advising hundreds of researchers annually. His research focuses on high-dimensional inference, statistical machine learning, and applications in genetics, political science, and climatology. He teaches courses such as Statistical Inference I, Reinforcement Learning, and Statistical Machine Learning. His work bridges theoretical advancements with practical applications, including contributions to robotics motion planning and microbiome data analysis. Key research areas include variable importance inference, safe reinforcement learning, compositional data analysis, and robust paleoclimate reconstructions. His methodologies are implemented in software packages like Floodgate, EigenPrism, and Fast Marching Tree (FMT*). He advises a dynamic group of PhD students and has mentored alumni now in academia and industry roles. Notable contributions include the development of model-X knockoffs for controlled variable selection, conditional randomization tests, and optimization algorithms for adaptive control systems. His work emphasizes statistical rigor while addressing real-world challenges in healthcare, environmental science, and robotics.
Dr. Matloob Khushi serves as a Senior Lecturer in Computer Science at Brunel University London's College of Engineering, Design and Physical Sciences. With over 25 years of combined academic and industry experience, his work bridges theoretical AI advancements with practical applications in finance, healthcare, and public health domains. His research has established significant collaborations with international banks, healthcare institutions, and technology startups. Dr. Khushi earned his PhD in AI and Data Science from the University of Sydney, developing novel algorithms for genomic data analysis. His postdoctoral research at the Children's Medical Research Institute (2014-2017) pioneered AI-based diagnostic tools for medical condition detection. More recently, he developed bioinformatics tools for environmental assessment under a UKRI NEC grant. Research Focus FinTech Innovation : Creator of the SS Ratio (incorporating volatility and drawdown sensitivities), advanced portfolio optimization models, and synthetic data generation techniques for fraud detection and credit risk assessment Bioinformatics Leadership : Developer of AI tools for genomic analysis and early cancer detection, featured in SBS News and The Daily Telegraph Public Health NLP : Architect of systems for vaccine misinformation detection, mental health monitoring, and health surveillance on social media His publication portfolio shows consistent growth from foundational bioinformatics work to current multimodal AI applications, with increasing interdisciplinary collaboration across finance and healthcare sectors. Awards and Recognition Ranked among Stanford/Elsevier's top 2% of global AI scientists Recipient of Best Paper Awards from IEEE Transactions on Computational Social Systems and PeerJ Media recognition for cancer detection research by major news outlets Mentorship and Teaching Dr. Khushi has supervised six PhD candidates to completion and over 100 postgraduate dissertations. He teaches CS3002 Artificial Intelligence and mentors students in Final Year Projects. His supervision focuses on Deep Learning/NLP for FinTech prediction and Public Health Surveillance applications, emphasizing practical implementation of theoretical concepts.
